TUE guidance documents including new regulations on glucocorticoids In order to assist physicians and athletes, in the last few weeks, WADA published the following guidance documents on managing TUEs to include the new regulations on glucocorticoids: General document on glucocorticoids and TUEs Checklists for athletes and treating physicians on a number of medical conditions for which glucocorticoids may be used TUE Physician Guidelines for TUE Committees on how to evaluate TUE requests for glucocorticoids for different medical conditions Educational resources In addition to the guidance documents listed above, WADA has provided a number of educational resources as part of its Code Implementation Support Program (CISP), which can be accessed on the Agencys Anti-Doping Education and Learning Platform (ADEL)
Jitteriness is not a commonly reported side effect of Mounjaro (tirzepatide), according to clinical trial data and the Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA)
Tesamorelin also increases natural growth hormone levels but is especially effective for reducing visceral fat and improving overall body composition
Furthermore, GHK-Cu peptide has shown promising results when used in combination with other active ingredients, such as retinoids, vitamin C, and hyaluronic acid, offering a synergistic approach to skin rejuvenation and overall skin health
